Home > News > Content

SZOB Welcomes Nabriva To Take The API Products For Lefamulin During The Phase III Clinical Trial

SZOB Welcomes Nabriva to Take the API Products for Lefamulin During the Phase III 

Clinical Trial


"There is a serious and growing public health threat as a result of the rise in increasingly difficult-to-treat 

bacterial infections." Nabriva plans to commence Phase III clinical trials for lefamulin.

Austria-based Nabriva Therapeutics has received qualified infectious disease product (QIDP) and fast-track 

status designation from the US Food and Drug Administration for its lefamulin (BC 3781).

The designation has been granted for lefamulin to treat community-acquired bacterial pneumonia (CABP) and 

acute bacterial skin and skin structure infections (ABSSSI).

Shenzhen Ok Biotech Technology Co., Ltd., known as SZOB, co-operated with factories to manage the quality 

of raw material of API and the  production of the APIs. All these production is strictly under GMP regulation. 

Till the March of 2017, SZOB can guarantee the stable supply for the phase III clinical trial. 

Tags: Nabriva, Nabriva Therapeutics, API, Lefamulin, BC 3781, bacterial infections, skin infections, 

forest labs